SCHEMBL203219

SCHEMBL203219

OB(O)c1ccc2c(c1)CCN2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.58
DRD4 P21917 1/20 0.58
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ENPP2 Q13822 1/20 0.39
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 4/20 0.36
ATM Q13315 1/20 0.36
ALOX15 P16050 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
THRB P10828 1/20 0.35
CASP1 P29466 1/20 0.35
HTT P42858 1/20 0.35
CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4608563 0.89 MAPT (0.54) DRD2DRD4MAPTKDM4EENPP2
SCHEMBL200682 0.85 DRD2 (0.44) DRD2DRD4MAPTENPP2CA1
SCHEMBL29953543 0.85 DRD2 (0.44) DRD2DRD4MAPTENPP2CA1
SCHEMBL2562600 0.75 PARP10 (0.58) KDM4E
SCHEMBL5757595 0.74 MAPT (0.42) DRD2DRD4MAPTKDM4EENPP2
SCHEMBL59263 0.74 DRD2 (1.00) DRD2DRD4MAPTKDM4ECA1
SCHEMBL4594796 0.73 NPC1 (0.50) MAPTCA9ALDH1A1HTTCYP2C9
SCHEMBL29756191 0.73 DRD2 (0.63) DRD2DRD4MAPTKDM4ECA1
SCHEMBL28403784 0.73 DRD2 (0.63) DRD2DRD4MAPTKDM4ECA1
Hydrochloric Acid SCHEMBL3900412 0.72 DRD2 (0.96) DRD2DRD4MAPTKDM4ECA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273744-B2 AMPK modulators MERCURY THERAPEUTICS, INC. (US) 2012-09-25 US disclosed
EP-2411358-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-8088936-B2 Leukotriene B4 inhibitors HOFFMAN-LA ROCHE INC. (US) 2012-01-03 US disclosed
WO-2010108856-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100240678-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2010-09-23 US disclosed
US-20100009992-A1 AMPK MODULATORS MERCURY THERAPEUTICS, INC. 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240678-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S DRD2 3062/4885DRD4 3497/4885MAPT 4334/4885
US-20100009992-A1 AMPK MODULATORS PRKAG1, PRKAG2, PRKAG3 DRD2 4762/4885DRD4 4790/4885MAPT 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.